---
title: "Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: References"
description: "Reference list for the formulary evidence report on Lonvoguran ziclumeran (lonvo-z, NTLA-2002) in Hereditary angioedema. 82 cited documents."
canonical: "https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/references"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: References

<a id="references"></a>

## 5 References

1. [Arora et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37558360/)
2. [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)
3. [Banerji et al. (2026)](https://www.intelliatx.com/wp-content/uploads/AAAAI-2026_Lonvo-z-New-Treatment-Goal-Poster_FINAL.pdf)
4. [Beard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9632406/)
5. [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)
6. [Broderick et al. (2025)](https://link.springer.com/article/10.1186/s41687-025-00876-3)
7. [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf)
8. [Busse et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41698689/)
9. [Castaldo et al. (2021)](https://www.researchgate.net/publication/349299347_Assessing_the_cost_and_quality-of-life_impact_of_on-demand-only_medications_for_adults_with_hereditary_angioedema)
10. [Cohn et al. (2025)](https://pure.amsterdamumc.nl/en/publications/crispr-based-therapy-for-hereditary-angioedema/)
11. [Cohn et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42294842/)
12. [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/)
13. [Craig et al. (2026)](https://karger.com/iaa/article/doi/10.1159/000553023/953095/Prevalence-and-Incidence-of-Hereditary-Angioedema)
14. [CSL (2023)](https://newsroom.csl.com/2023-03-01-The-Lancet-Publishes-Pivotal-Phase-3-Data-on-CSLs-First-in-Class-Garadacimab-for-HAE)
15. [CSL Behring (2022)](https://labeling.cslbehring.com/PI/US/HAEGARDA/EN/HAEGARDA-Prescribing-Information.pdf)
16. [CSL Behring (2026)](https://www.haegarda.com/hcp/efficacy)
17. [EU Clinical Trials Register 2013-000916-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000916-10/ES)
18. [Farkas and Balla (2024)](https://pubmed.ncbi.nlm.nih.gov/38366937/)
19. [FDA (2018)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf)
20. [FDA (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf)
21. [FDA ANDEMBRY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761367s000lbl.pdf)
22. [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)
23. [FDA Drug Trials Snapshots ANDEMBRY (2025)](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-andembry)
24. [FDA Drug Trials Snapshots DAWNZERA (2025)](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-dawnzera)
25. [FDA Drug Trials Snapshots EKTERLY (2025)](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-ekterly)
26. [Feld et al. (2026)](https://link.springer.com/article/10.1186/s41687-026-01128-8)
27. [Guan et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03265-z)
28. [Henao et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4859422/)
29. [ICER (2021)](https://icer.org/wp-content/uploads/2020/10/ICER_Aetion_RWE_HAE_Report_082421.pdf)
30. [Intellia Therapeutics (2022)](https://www.globenewswire.com/news-release/2022/09/01/2508902/0/en/Intellia-Therapeutics-Receives-U-S-FDA-Orphan-Drug-Designation-for-NTLA-2002-an-Investigational-CRISPR-Therapy-for-the-Treatment-of-Hereditary-Angioedema.html)
31. [Intellia Therapeutics (2023)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fda-regenerative-medicine)
32. [Intellia Therapeutics (2024)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-presents-positive-results-phase-2-study-ntla-2002)
33. [Intellia Therapeutics (2025)](https://www.sec.gov/Archives/edgar/data/0001652130/000095017025028373/ntla-ex99_1.htm)
34. [Intellia Therapeutics AAAAI poster (2025)](https://www.intelliatx.com/wp-content/uploads/CRISPR-Based-NTLA-2002-Improves-Quality-of-Life-in-Patients-With-Hereditary-Angioedema.pdf)
35. [Intellia Therapeutics AAAAI presentation (2021)](https://www.intelliatx.com/wp-content/uploads/AAAAi_2021_NTLA_HAE_27Feb2021.pdf)
36. [Intellia Therapeutics ACAAI poster (2025)](https://www.intelliatx.com/wp-content/uploads/ACAAI-2025_Lonvo-z-Ph1-2-Safety_Poster_FINAL.pdf)
37. [Intellia Therapeutics ACAAI presentation (2025)](https://www.intelliatx.com/wp-content/uploads/ACAAI-2025_Lonvo-z-Ph1-2-50mg-and-LTFU_Oral_FINAL.pdf)
38. [Intellia Therapeutics additional HAELO phase 3 results announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-additional-positive-phase-3)
39. [Intellia Therapeutics BLA acceptance announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fda-acceptance-biologics-license)
40. [Intellia Therapeutics corporate overview (2026)](https://ir.intelliatx.com/static-files/a57908a6-aaca-404d-9072-32471cd3d41e)
41. [Intellia Therapeutics EAACI presentation (2025)](https://www.intelliatx.com/wp-content/uploads/EAACI-2025_NTLA-Ph1-Durability_Oral_FINAL.pdf)
42. [Intellia Therapeutics EAACI presentation (2026)](https://www.intelliatx.com/wp-content/uploads/HAELO-EAACI-2026-Presentation_FINAL.pdf)
43. [Intellia Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm)
44. [Intellia Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1652130/000119312526337952/ntla-20260630.htm)
45. [Intellia Therapeutics HAELO first patient dosed announcement (2025)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-patient-dosed-haelo-phase)
46. [Intellia Therapeutics HAELO phase 3 results announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-positive-phase-3-results)
47. [Intellia Therapeutics HAELO topline data presentation (2026)](https://ir.intelliatx.com/static-files/d76952d4-4a66-4ab1-b38d-4856721edea3)
48. [Intellia Therapeutics investor presentation (2024)](https://www.intelliatx.com/wp-content/uploads/Intellia_NTLA-2002-Phase-2-Data-Investor-Presentation_10.24.24_vF.pdf)
49. [Intellia Therapeutics presentation (2026)](https://ir.intelliatx.com/node/12426/html)
50. [Intellia Therapeutics rolling BLA submission announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-initiates-rolling-submission-biologics)
51. [Intellia Therapeutics third quarter 2026 results (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-third-quarter-2026-financial)
52. [Ionis Pharmaceuticals protocol and statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/10/NCT05139810/Prot_SAP_000.pdf)
53. [Jalal et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12688763/)
54. [Kaplan et al. (2026)](https://www.intelliatx.com/wp-content/uploads/AAAAI-2026_KKS-Modeling-Poster_with-Supplement.pdf)
55. [Kutrieb et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13151981/)
56. [Longhurst et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28328347/)
57. [Longhurst et al. (2023)](https://www.intelliatx.com/wp-content/uploads/Longhurst_H_C1INH_06.05.2023_Transient-exposure-to-NTLA-2002-an-investigational-CRISPR_CAS9-based-gene-editing-therapy-leads-to-durable-PD-responses-and-attack-control-in-HAE-vf.pdf)
58. [Longhurst et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38294975/)
59. [Lumry et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/all.14680)
60. [Luong et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42504735/)
61. [Magerl et al. (2026)](https://www.intelliatx.com/wp-content/uploads/AAAAI-2026_Lonvo-z-Durability-Update_Poster_FINAL-1.pdf)
62. [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)
63. [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)
64. [Olson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41429313/)
65. [Pardi and Ivics (2024)](https://pubmed.ncbi.nlm.nih.gov/38925443/)
66. [Princic et al. (2025)](https://becaris.figshare.com/articles/dataset/Supplementary_materials_Comparison_of_real-world_healthcare_resource_utilization_and_costs_among_patients_with_hereditary_angioedema_on_lanadelumab_or_berotralstat_long-term_prophylaxis/28450706)
67. [Riedl et al. (2024a)](https://pure.amsterdamumc.nl/en/publications/clinical-progress-in-hepatic-targeting-for-novel-prophylactic-the)
68. [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)
69. [Sandberg et al. (2024)](https://medicaljournalssweden.se/actadv/article/view/24176)
70. [Somatic Cell Gene Editing Consortium NCT05120830](https://scge.mcw.edu/platform/data/report/clinicalTrials/NCT05120830)
71. [Somatic Cell Gene Editing Consortium NCT06634420](https://scge.mcw.edu/platform/data/report/clinicalTrials/NCT06634420)
72. [Uminski et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12618362/)
73. [US Hereditary Angioedema Association](https://www.haea.org/)
74. [Vanya et al. (2023)](https://link.springer.com/article/10.1186/s41687-023-00576-w)
75. [Vázquez et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42165046/)
76. [Villa et al. (2026)](https://link.springer.com/article/10.1007/s40271-025-00798-8)
77. [Walsh et al. (2022)](https://www.intelliatx.com/wp-content/uploads/AAAAi-Scientific-Poster_01.5_Final.pdf)
78. [Walsh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40434599/)
79. [Watt et al. (2026)](https://link.springer.com/article/10.1186/s13023-025-04134-z)
80. [Weller et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27038109/)
81. [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/)
82. [Zuraw et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40300843/)

## Related pages
- [Lonvoguran ziclumeran (lonvo-z): Hereditary angioedema](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Terms and abbreviations](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/terms-and-abbreviations.md)
- [Lonvoguran ziclumeran (lonvo-z): Hereditary angioedema](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/executive-summary.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Product information and disease description](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/product-information-and-disease-description.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Clinical evidence](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/clinical-evidence.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Economic information and modeling report](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/economics) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/economics.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: prevalence by geography](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/prevalence) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/prevalence.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/cost-effectiveness-analyses.md)
